Drug Policy Archives - Page 8 of 56

Rethinking the need for double-blind placebo trials in psychedelic clinical investigations

Commentary by Madison Carlino

Psychedelic treatment for neurodegenerative disorders

Policy Brief by Madison Carlino

Psychedelic therapy offers possible new hope for Alzheimer’s disease sufferers

Commentary by Madison Carlino

Nonconsensual drug testing raises serious ethical concerns

Commentary by Layal Bou Harfouch

Harm reduction recommendations for the Trump administration

Commentary by Layal Bou Harfouch

Intoxicating hemp products in Ohio need regulation, not prohibition

Commentary by Michelle Minton

Batch-tracking: The next wave of marijuana tracking systems

Commentary by Madison Carlino and Geoffrey Lawrence

Psychedelics Policy Newsletter: Trump administration recommendations, Massachusetts loss, and more

Psychedelics Policy Newsletter by Gregory Ferenstein

State psychedelics legalization and policy roundup — December 2024

Commentary by Gregory Ferenstein

More Drug Policy